Jeffrey Zonder, MD
Enriched profileProfessor - Clinical, Department of Oncology, Wayne State University School of Medicine · Wayne State University School of Medicine
Jeffrey Zonder is Professor - Clinical, Department of Oncology, Wayne State University School of Medicine at Wayne State University School of Medicine. OpenAlex indexes 369 publications with 12,843 citations (h-index 52); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Jeffrey Zonder, MD, is Professor - Clinical, Department of Oncology, Wayne State University School of Medicine. The public record shows 369 publications with 12,843 citations (h-index 52), centered on Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Bone health and treatments. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 14 companies.
- Most recent indexed publication: 2024 · Journal of clinical oncology
- Top research focus: Multiple Myeloma Research and Treatments
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 135.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Sponsor: Barbara Ann Karmanos Cancer Institute
- Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Sponsor: Barbara Ann Karmanos Cancer Institute
- Dietary Reporting In The Amyloidoses
Sponsor: Barbara Ann Karmanos Cancer Institute
Industry payments
Updated 16 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20252 payments
- Regeneron Pharmaceuticals, Inc.Program year20254 payments
- PFIZER INC.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
85.6%Thalidomide Analog85.6%Revlimid45%Pomalyst30%Lenalidomide25%Part D≥24 patientsDermatology
8.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor8.1%Acyclovir100%Part D≥12 patientsAnti-infectives
6.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor6.3%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
103 congress contributions (2005–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 420: Targeting proliferating cell nuclear antigen via a miRNA-CSC axis as a new therapeutic approach in multiple myeloma.
AACR Annual Meeting
AACR2026Presenting author - Final analysis of daratumumab, carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Journal of clinical oncology
Clinical Trial2024 - A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.
European journal of haematology
Clinical Trial2023 - Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.
JCO oncology practice
Article2020 - Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
British journal of haematology
Clinical Trial2019 - Daratumumab proves safe and highly effective in AL amyloidosis.
British journal of haematology
Article2019
Most-cited works
by citation count (OpenAlex)- 01
- 02Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaArticle842 citations2007
- 03
- 04Daratumumab-Based Treatment for Immunoglobulin Light-Chain AmyloidosisArticle702 citations2021
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jeffrey-zonder-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
karmanos.org/karmanos/news/in-the-news-dr-zonder-on-the-management-of-bispeci-4482
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →karmanos.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗
- Board certified
American Board of Internal Medicine, Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗
- Member
International Myeloma Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗ - Member
American Society of Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗ - Member
American Society of Clinical Oncologists
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗ - Member
International Society of Amyloidosis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗ - Member
Hematology News Editorial Advisory Board
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →amyloidosissupport.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.med.wayne.edu ↗
Secondary affiliations
appointments beyond the home institution- Barbara Ann Karmanos Cancer Institute; Leader
Multiple Myeloma and Amyloidosis Multidisciplinary Team
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →waynehealthcares.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →waynehealthcares.org ↗
- OncLive author profile
Jeffrey Zonder, MD
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Tinnakorn Chaiworapongsa, MD
Wayne State University School of Medicine
Peter Lewitt, MD
Wayne State University School of Medicine
Bernard Gonik, MD
Wayne State University School of Medicine
Teena Chopra, MD
Wayne State University School of Medicine
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens